| Trial watch: STING agonists in cancer therapy J Le Naour, L Zitvogel, L Galluzzi, E Vacchelli, G Kroemer Oncoimmunology 9 (1), 1777624, 2020 | 230 | 2020 |
| Trial watch: IDO inhibitors in cancer therapy J Le Naour, L Galluzzi, L Zitvogel, G Kroemer, E Vacchelli Oncoimmunology 9 (1), 1777625, 2020 | 123 | 2020 |
| Gut microbiota-stimulated innate lymphoid cells support β-defensin 14 expression in pancreatic endocrine cells, preventing autoimmune diabetes M Miani, J Le Naour, E Waeckel-Enée, S chand Verma, M Straube, ... Cell metabolism 28 (4), 557-572. e6, 2018 | 96 | 2018 |
| Trial watch: TLR3 agonists in cancer therapy J Le Naour, L Galluzzi, L Zitvogel, G Kroemer, E Vacchelli Oncoimmunology 9 (1), 1771143, 2020 | 85 | 2020 |
| Trial Watch: experimental TLR7/TLR8 agonists for oncological indications G Frega, Q Wu, J Le Naour, E Vacchelli, L Galluzzi, G Kroemer, O Kepp Oncoimmunology 9 (1), 1796002, 2020 | 77 | 2020 |
| A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice S Lévesque, J Le Naour, F Pietrocola, J Paillet, M Kremer, F Castoldi, ... Oncoimmunology 8 (11), e1657375, 2019 | 69 | 2019 |
| A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency J Le Naour, P Liu, L Zhao, S Adjemian, Z Sztupinszki, J Taieb, C Mulot, ... Cancer Discovery 11 (2), 408-423, 2021 | 36 | 2021 |
| Trial watch: intratumoral immunotherapy J Humeau, J Le Naour, L Galluzzi, G Kroemer, JG Pol Oncoimmunology 10 (1), 1984677, 2021 | 36 | 2021 |
| The ambiguous role of FPR1 in immunity and inflammation E Vacchelli, J Le Naour, G Kroemer Oncoimmunology 9 (1), 1760061, 2020 | 31 | 2020 |
| Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma J Paillet, C Plantureux, S Lévesque, J Le Naour, G Stoll, A Sauvat, ... Journal of Experimental Medicine 218 (10), e20200853, 2021 | 22 | 2021 |
| FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin GK Jonathan G. Pol, Julie Le Naour OncoImmunology 9 (1), 2020 | 16 | 2020 |
| Local anesthetics elicit immune-dependent anticancer effects L Bezu, AW Chuang, A Sauvat, J Humeau, W Xie, G Cerrato, P Liu, ... Journal for immunotherapy of cancer 10 (4), 2022 | 14 | 2022 |
| Trial watch: Toll-like receptor ligands in cancer therapy J Le Naour, G Kroemer Oncoimmunology 12 (1), 2180237, 2023 | 11 | 2023 |
| No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19 A Petrazzuolo, J Le Naour, E Vacchelli, P Gaussem, S Ellouze, G Jourdi, ... OncoImmunology 9 (1), 1857112, 2020 | 10 | 2020 |
| A major genetic accelerator of cancer diagnosis: rs867228 in FPR1 Z Sztupinszki, J Le Naour, E Vacchelli, P Laurent-Puig, S Delaloge, ... Oncoimmunology 10 (1), 1859064, 2021 | 9 | 2021 |
| Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer V Carbonnier, J Le Naour, T Bachelot, E Vacchelli, F André, S Delaloge, ... Oncoimmunology 12 (1), 2189823, 2023 | 7 | 2023 |
| Improved Swiss-rolling method for histological analyses of colon tissue J Le Naour, L Montégut, A Joseph, K Garbin, E Vacchelli, G Kroemer, ... MethodsX 9, 101630, 2022 | 7 | 2022 |
| Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis J Le Naour, L Montégut, Y Pan, SA Scuderi, P Cordier, A Joseph, ... Oncoimmunology 12 (1), 2237354, 2023 | 4 | 2023 |
| A chemically defined TLR3 agonist with anticancer activity J Le Naour, S Thierry, SA Scuderi, M Boucard-Jourdin, P Liu, M Bonnin, ... Oncoimmunology 12 (1), 2227510, 2023 | 3 | 2023 |
| A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients J Le Naour, Z Sztupinszki, V Carbonnier, O Casiraghi, V Marty, L Galluzzi, ... Oncoimmunology 11 (1), 2059878, 2022 | 3 | 2022 |
